Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
Consolidated revenues grew 2% year-over-year in 2024, with ATM revenues increasing 3%. Advanced packaging and testing revenues surged to $600M, up from $250M in 2023, driven by strong demand in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback